Exact Sciences Corporation (EXAS): Price and Financial Metrics

Exact Sciences Corporation (EXAS)

Today's Latest Price: $150.00 USD

1.93 (1.30%)

Updated Jan 22 4:00pm

Add EXAS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

EXAS Stock Summary

  • With a market capitalization of $22,563,605,250, Exact Sciences Corp has a greater market value than 89.91% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Exact Sciences Corp is reporting a growth rate of 179.92%; that's higher than 92.29% of US stocks.
  • Revenue growth over the past 12 months for Exact Sciences Corp comes in at 82.48%, a number that bests 93.57% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to EXAS, based on their financial statements, market capitalization, and price volatility, are AKAM, WST, LOGI, HZNP, and NDAQ.
  • EXAS's SEC filings can be seen here. And to visit Exact Sciences Corp's official web site, go to www.exactsciences.com.

EXAS Stock Price Chart Interactive Chart >

Price chart for EXAS

EXAS Price/Volume Stats

Current price $150.00 52-week high $152.87
Prev. close $148.07 52-week low $35.25
Day low $146.20 Volume 1,370,000
Day high $150.32 Avg. volume 1,906,864
50-day MA $131.19 Dividend yield N/A
200-day MA $99.88 Market Cap 22.56B

Exact Sciences Corporation (EXAS) Company Bio

Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin.

EXAS Latest News Stream

Event/Time News Detail
Loading, please wait...

EXAS Latest Social Stream

Loading social stream, please wait...

View Full EXAS Social Stream

Latest EXAS News From Around the Web

Below are the latest news stories about Exact Sciences Corp that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

Exact Sciences: Patching The Acquisitions Together

The current cancer treatments lack efficiency, and late diagnostics make everything harder. As a matter of fact, experts have been telling us for a long time that early detection is fundamental to have a significant increase in survival rates. The holy grail for early cancer detections could be a blood...

Nelson Alves on Seeking Alpha | January 21, 2021

Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp. By Investing.com

Leerink Partners Stick to Their Buy Rating for Exact Sciences Corp.

Investing.com | January 21, 2021

Cologuard accurately screens younger individuals for colorectal cancer

The U.S. Preventive Services Task Force (USPSTF) appears on the verge of expanding colorectal cancer screening to individuals ages 45 to 49, based on its latest draft recommendations. If it does, Exact Sciences Corp. is ready. A study in Cancer Prevention Research demonstrated that the Madison, Wis.-based company's Cologuard multitarget stool DNA test had better than 95% specificity in individuals with nonadvanced precancerous lesions or negative findings on colonoscopy.

BioWorld | January 15, 2021

Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology

Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. This compelling and technically distinct approach will help expand Exact Sciences' leadership in precision oncology and offers a differentiated patient-specific solution in minimal residual disease testing.

Yahoo | January 13, 2021

Sidoti Virtual Investor Conference

Presentation Times and Weblinks Released for Over 60 Presenting CompaniesNEW YORK, NY / ACCESSWIRE / January 13, 2021 / Sidoti & Company, LLC has released the presentation schedule, with weblink click-throughs, for its two-day Winter 2021 Virtual Investor Conference, to take place Wednesday and Thursday, January 13-14, 2021. The links can also be found at www.

Yahoo | January 13, 2021

Read More 'EXAS' Stories Here

EXAS Price Returns

1-mo N/A
3-mo 40.75%
6-mo 58.21%
1-year 67.47%
3-year 198.45%
5-year 2,148.88%
YTD 13.22%
2020 43.26%
2019 46.56%
2018 20.10%
2017 293.26%
2016 44.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8011 seconds.